With their "insatiable need for capital," the biotech and pharmaceutical industries will continue to see a healthy M&A market, regardless of what happens in the macroeconomy, says Gregory Brown, co-founder and managing director, Cowen Healthcare Royalty Partners, a healthcare private equity firm. For more, see his column "The new normal" in the current issue of The Deal magazine.